EoE HCP Educational UK Roadshow

An educational EoE Roadshow is coming to cities across the UK, offering an excellent opportunity for HCPs to learn more about the fast-changing landscape of eosinophilic oesophagitis. Read more

New Clinical Severity Index for Management of EoE

The Index, produced by CEGIR researchers, is another step towards global consensus, and is designed to help HCPs monitor EoE severity to make informed decisions about treatment and management. Read more

Positive clinical results for treating EoE in under 12s

July 2022 - A trial investigating dupilimab to treat children under 12 with EoE has achieved positive results. This follows the FDA's approval of dupilimab to treat EoE in adults and children 12 and over earlier this year. Read more

First USA drug approved for EoE

After many years of the USA having no approved treatment options for EoE. Approval for use has been announced for a new biologic injection. Read more

EOS Network at BSG Live '22

The upcoming EoE Guidelines will be released and presented at the British Society for Gastroenterology BSG Live Annual Meeting from 22-23 June. EOS Network will be exhibiting at the event, alongside Guidelines committee chair Professor Anjan Dhar and other co-authors. Read more

Meet Sean Goss, Professional Footballer & EOS Network Ambassador

Sean Goss is a professional footballer with EoE. His journey will be familiar to many living with the condition - adapting lifestyle and struggling to find a correct diagnosis. We're proud to have him as an ambassador for our charity. Read more

Improving Care in Eosinophil-Associated Diseases: A Charter

A Charter outlining the key rights and expectations for people living with eosinophil-associated diseases. It proposes four key principles that will patients should expect from the management of their conditions and set a basic standardisation of care. Read more

Should patients with IgE allergies be screened for EoE?

A short study has shown a correlation in children with IgE-mediated food allergies reporting symptoms of eosinophilic oesophagitis (EoE), leading researchers to suggest that it may be beneficial to screen IgE-FA patients for EoE. Read more

Increasing EOS Awareness Among Allergy and Immunology Healthcare Professionals

Check out our volunteer's report from exhibiting at the World Allergy Organisation and British Society of Allergy and Clinical Immunology Conference in April 2022 Read more

Public and Healthcare Professional Awareness of EoE

On behalf of Dr Falk Pharma UK, Healthy PR are looking for adults with EoE who are looking to share their story to help spread awareness of the disease. If you want to get involved, here's how to apply. Read more

International Consensus Recommendations for EGID nomenclature

A publication in Clinical Gastroenterology and Hepatology has made an important step towards developing international consensus for EGID terminology. Read more

Announcing our new Treasurer!

Introducing EOS Network's new Trustee Treasurer, Ben McGrath. Ben has over 30 years' experience in the sector. Read more

EAW 22 - Save the Date!

Save the date in your diaries - Eosinophil Awareness Week (EAW) will take place 16th - 22nd May this year! It's an opportunity to promote awareness of EGIDs and show support for those living with eosinophilic diseases. Read more

London International Upper GI Symposium

The London International Upper GI Symposium (LUGIS) is returning this year on Friday 29th April. The day includes a presentation on the new British EoE Guideline. See the full programme and register here. Read more

First UK Patient in MESSINA EoE Trial

The first UK patient has been recruited for the global MESSINA study for benralizumab for EoE. Find study details and see if you're eligible to take part in the Phase 3 trial. Read more

Lirentelimab studies meet histologic endpoints but miss symptomatic endpoints

Allakos has announced that it's ENIGMA (Phase 3) and KRYPTOS (Phase 2/3) studies for lirentelimab in EG & EoD and EoE respectively met histologic endpoints but missed symptomatic endpoints. Read more

FDA rejects application for budesonide treatment

The US FDA has rejected an application for TAK-721 (budesonide oral suspension) for the treatment of EoE in it's present form, and have recommended an additional study to help resolve feedback. Read more

ESPGHAN 2021 - EoE: The Patient's Experience

We are proud that our Chair and Founder was invited to present at the ESPGHAN Eosinophilic Gastrointestinal Diseases monothematic conference - Advocating for patients across Europe. Read More Read more

Post-Doctoral Researcher & Research Assistant Opportunities

Two opportunities are available, a Post-Doctoral Researcher and Research Assistant, in the Allergy, Inflammation & Remodelling Research (AIRR) Laboratory of Dr. Joanne Masterson at Maynooth University, Northern Ireland. Read more

Warmest wishes to David Evans

Our Treasure and Trustee David Evans will be retiring at the end of the year and we would like to thank him for his service to the EOS Community. Read more